Invitrogen last week said that Norman Russell has joined the company as vice president and general manager of the functional genomics strategic business unit.
In this role, Invitrogen said, Russell will lead the company’s genomics, proteomics, and RNAi product lines. He joins Invitrogen from Aviva Biosciences, where he served as president and CEO. Prior to that, Russell was president and CEO of Lynx Therapeutics. He also served for many years for AstraZeneca, Invitrogen said. Russell holds a PhD in physiology from Glasgow University.
Al Kolb is currently serving as the 2004-2005 president elect for the Society for Biomolecular Screening, the organization announced last week. He will assume the presidency at the society’s 11th Annual Conference and Exhibition to be held Sept. 11-15 in Geneva.
Kolb is a consultant for KeyTechnology Consulting in Madison, Conn. He was one of the founding members of the society, SBS said, and a member of the first board of directors in 1994, and from 1999 through 2000. He has also served as a member of the editorial board of the Journal of Biomolecular Screening since its inception. Kolb holds a PhD in molecular biology from the University of California, Irvine, and completed a postdoctoral fellowship at the Roche Institute for Molecular Biology.